The thyroid warning on Wegovy is real, but it comes from animal studies, and the human data so far point in two directions. This page sets the label's own words next to the two largest studies of people taking GLP-1 drugs, so you can see what is known and what isn't. Wegovy contains semaglutide, the same molecule as Ozempic, and both carry the same boxed warning [1] [2].
Wegovy's boxed warning comes from rodent studies
The warning is based on mice and rats, and the label says human relevance hasn't been determined. In two-year studies, semaglutide raised the rate of thyroid C-cell tumors in both species at exposures similar to those people get [1]. C-cells are the calcitonin-making cells of the thyroid; medullary thyroid carcinoma (MTC) is the cancer that starts in them.
It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.[1]
The label adds that the human relevance of the rat findings "could not be determined by clinical studies or nonclinical studies" [1]. Rodents have far more C-cells than people do, which is one reason the question stays open, but the label itself makes no claim either way. Tirzepatide, the drug in Mounjaro and Zepbound, carries the same type of boxed warning from its own rat studies [3]; see tirzepatide side effects.
| Statement on the label | Where |
|---|---|
| Semaglutide caused thyroid C-cell tumors in mice and rats at clinically relevant exposures | Boxed warning; 5.1; 13.1 |
| Whether Wegovy causes these tumors in people is unknown | Boxed warning; 5.1 |
| MTC cases with liraglutide reported after approval are "insufficient to establish or exclude a causal relationship" | 5.1 |
| Don't use with a personal or family history of MTC, or with MEN 2 | Boxed warning; 4 |
| Routine calcitonin tests or thyroid ultrasound are "of uncertain value" and may lead to unnecessary procedures | 5.1 |
| Thyroid nodules found on an exam or imaging "should also be further evaluated" | 5.1 |
| Report a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath | Medication Guide |
Wegovy prescribing information, June 2026 version.
Has anyone gotten thyroid cancer on Wegovy?
The label doesn't report confirmed cases caused by Wegovy. What it does report is a postmarketing note about a different drug: "Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship" [1].
Postmarketing reports are cases sent in by doctors and patients after a drug is on sale. They show that something happened while a person was on a drug. They can't show the drug caused it, and they can't give a rate, because nobody knows how many people took the drug without a problem. The Wegovy label prints no thyroid cancer counts from its own trials.
So the honest answer to the search question is that individual reports exist for the drug class, and the studies built to measure risk in large groups don't agree. Those studies are the better guide, and they're below.
The two largest human studies point in different directions
A French study found more thyroid cancer after 1 to 3 years of GLP-1 use; a larger Scandinavian study found no clear increase. Neither studied Wegovy itself. Both looked at GLP-1 drugs as a class in people with type 2 diabetes.
| Study | Data | Who | Design | Result (95% CI) | Funding and ties |
|---|---|---|---|---|---|
| Bezin 2023, Diabetes Care [4] | French national health insurance database | Adults with type 2 diabetes on second-line diabetes drugs, 2006 to 2018; 2,562 thyroid cancer cases matched with 45,184 controls | Nested case-control; GLP-1 use measured over the 6 years before diagnosis | 1 to 3 years of use: all thyroid cancer 1.58 (1.27 to 1.95); medullary 1.78 (1.04 to 3.05) | Academic authors; funding not listed in the abstract |
| Pasternak 2024, BMJ [5] | Nationwide registers in Denmark, Norway and Sweden, 2007 to 2021 | 145,410 people starting a GLP-1 drug vs 291,667 starting a DPP-4 inhibitor | Active-comparator new-user cohort; mean follow-up 3.9 years | All thyroid cancer 0.93 (0.66 to 1.31); medullary 1.19 (0.37 to 3.86); vs SGLT2 starters 1.16 (0.65 to 2.05) | Support included the Novo Nordisk Foundation among several public funders; one author reported fees from drugmakers outside the study |
A hazard ratio above 1 means more cancers in the GLP-1 group; a confidence interval that crosses 1 means the result is compatible with no difference.
In the Scandinavian study, 76 of 145,410 GLP-1 users and 184 of 291,667 DPP-4 users developed thyroid cancer, about 1.3 and 1.5 cases per 10,000 person-years [5]. Its authors say the upper end of their main result is consistent with "no more than a 31% increase in relative risk."
The drug mix matters for a Wegovy reader. In the Scandinavian study, 57.3% of GLP-1 users started on liraglutide and 32.9% on semaglutide, and semaglutide users were followed for only 1.1 years on average [5]. The study's authors call for future work on each GLP-1 drug separately. The medullary cancer results in both studies rest on small numbers, which is why their confidence intervals are wide.
Why the studies disagree
Different designs, different comparison groups and the chance of finding more cancers in people who get more thyroid checks can all move a result. Neither study can settle the question by itself.
- Comparison group. The French study compared people with thyroid cancer to matched people without it, within everyone on second-line diabetes drugs [4]. The Scandinavian study compared new GLP-1 users only with new users of another diabetes drug class, a design its authors chose to reduce confounding [5].
- Detection. The Scandinavian authors suggest the French result could reflect detection bias: people starting a drug with a thyroid warning may get more neck exams and imaging, which finds more small cancers. They saw a small rise limited to the first year of treatment, which they call consistent with more detection rather than a drug effect [5].
- Time. Cancers can take years to appear. The Scandinavian authors list latency as a limitation and note that a quarter of their participants were followed for 6.1 years or longer [5].
The French paper drew six published comments in the same journal within months [4], which is normal for a result that matters this much. What would settle it is longer follow-up of semaglutide users specifically, which neither study had.
Who should not take Wegovy
Anyone with a personal or family history of medullary thyroid carcinoma, or with MEN 2, should not use Wegovy [1]. The Medication Guide calls MEN 2 "an endocrine system condition," and it is inherited. MedlinePlus explains that the most common sign of multiple endocrine neoplasia type 2 is medullary thyroid carcinoma [6]. The label also rules Wegovy out after a serious allergic reaction to semaglutide or the product's ingredients [1].
Should you get thyroid tests on Wegovy?
Not routinely, according to the label. It says routine calcitonin tests or thyroid ultrasound are "of uncertain value for early detection of MTC" and "may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease" [1].
The label is clear about what should happen if something turns up: an elevated calcitonin result should be followed up, and nodules found on a physical exam or neck imaging "should also be further evaluated" [1]. Tell your prescriber about any nodule you already know about before you start.
Symptoms to report
A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. The Medication Guide asks you to tell your healthcare provider about any of these, because they "may be symptoms of thyroid cancer" [1]. Most neck lumps aren't cancer, but they are worth an exam.
What this means if you're weighing Wegovy
If MTC or MEN 2 runs in your family, Wegovy isn't an option. For everyone else, the thyroid question is an open one that large studies haven't resolved, set against the drug's known benefits and its more common risks. Those are covered in Wegovy side effects and is Wegovy safe. The same thyroid warning applies to Ozempic; see Ozempic safety and side effects.
Questions worth bringing to the appointment: does anything in my own or my family's thyroid history matter here; should a nodule I already have be checked before I start; and which neck symptoms should make me call between visits.
Compounded semaglutide carries the same molecule and so the same open question, plus quality questions of its own; see is compounded semaglutide safe. Other cancers fall outside this page; the label's cancer warning is about thyroid C-cell tumors.
Weighing programs on price? The brand Wegovy and Zepbound self-pay programs lineup sets 21 of them side by side, each with its true monthly cost.